Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-κB pathways

Journal of Medicinal Chemistry

Volumn 52, Issue 7, 2009, Pages 1903-1911

  Lin, Jau Chen ^a   Yang, Shuenn Chen ^a   Hong, Tse Ming ^c   Yu, Sung Liang ^c   Qian, Shi ^b   Linyi, Wei ^b   Chen, Hsuan Yu ^d   Yang, Pan Chyr ^e   Lee, Kuo Hsiung ^b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b University of North Carolina   (United States)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARISOPRODOL; CYCLOOXYGENASE 2; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHENANTHRENE BASED TYLOPHORINE 1; PHENANTHRENE BASED TYLOPHORINE 10; PHENANTHRENE BASED TYLOPHORINE 2; PHENANTHRENE BASED TYLOPHORINE 3; PHENANTHRENE BASED TYLOPHORINE 4; PHENANTHRENE BASED TYLOPHORINE 5; PHENANTHRENE BASED TYLOPHORINE 6; PHENANTHRENE BASED TYLOPHORINE 7; PHENANTHRENE BASED TYLOPHORINE 8; PHENANTHRENE BASED TYLOPHORINE 9; PHENANTHRENE DERIVATIVE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELB; TYLOPHORINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DRUG EFFECT; DRUG STRUCTURE; FOCAL ADHESION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FOCAL ADHESIONS; G2 PHASE; GENE EXPRESSION REGULATION; HUMANS; LUNG NEOPLASMS; NF-KAPPA B; PHENANTHRENES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC;

EID: 64549149739     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801344j     Document Type: Article

References (52)

1. Wu, P. L.; Rao, K. V.; Su, C. H.; Kuoh, C. S.; Wu, T. S. Phenanthroindolizidine alkaloids and their cytotoxicity from the leaves of Ficus septica. Heterocycles 2002, 57, 2401-2408.
2. Li, Z.; Jin, Z.; Huang, R. Isolation, total synthesis and biological activity of phenanthroindolizidine and phenanthroquinolizidine alkaloids. Synthesis 2001, 16, 2365-2378.
3. Wei, L.; Brossi, A.; Kendall, R.; Bastow, K. F.; Morris-Natschke, S. L.; Shi, Q.; Lee, K. H. Antitumor agents 251: synthesis, cytotoxic evaluation, and structure-activity relationship studies of phenanthrenebased tylophorine derivatives (PBTs) as a new class of antitumor agents. Bioorg. Med. Chem. 2006, 14, 6560-6569.
4. Wei, L.; Shi, Q.; Bastow, K. F.; Brossi, A.; Morris-Natschke, S. L.; Nakagawa-Goto, K.; Wu, T. S.; Pan, S. L.; Teng, C. M.; Lee, K. H. Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents. J. Med. Chem. 2007, 50, 3674-3680.
5. Staerk, D.; Lykkeberg, A. K.; Christensen, J.; Budnik, B. A.; Abe, F.; Jaroszewski, J. W. In vitro cytotoxic activity of phenanthroindolizidine alkaloids from Cynanchum Vincetoxicum and Tylophora tanakae against drug-sensitive and multidrug-resistant cancer cells. J. Nat. Prod. 2002, 65, 1299-1302.
6. Ganguly, T.; Khar, A. Induction of apoptosis in a human erythroleukemic cell line K562 by tylophora alkaloids involves release of cytochrome c and activation of caspase 3. Phytomedicine 2002, 9, 288-295.
7. Komatsu, H.; Watanabe, M.; Ohyama, M.; Enya, T.; Koyama, K.; Kanazawa, T.; Kawahara, N.; Sugimura, T.; Wakabayashi, K. Phenanthroindolizidine alkaloids as cytotoxic substances in a Danaid butterfly, Ideopsis similis, against human cancer cells. J. Med. Chem. 2001, 44, 1833-1836.
8. Rao, K. N.; Venkatachalam, S. R. Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. Toxicol. in Vitro 2000, 14, 53-59.
9. Rao, K. N.; Bhattacharya, R. K.; Venkatachalam, S. R. Inhibition of thymidylate synthase and cell growth by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine. Chem. Biol. Interact. 1997, 106, 201-212.
10. Rao, K. V.; Wilson, R. A.; Cummings, B. Alkaloids of tylophora. 3. New alkaloids of Tylophora indica(Burm) Merrill and Tylophora dalzellii Hook. f. J. Pharm. Sci. 1971, 60, 1725-1726.
11. Gupta, R. S.; Siminovitch, L. Mutants of CHO cells resistant to the protein synthesis inhibitors, cryptopleurine and tylocrebrine: genetic and biochemical evidence for common site of action of emetine, cryptopleurine, tylocrebine, and tubulosine. Biochemistry 1977, 16, 3209-3214.
12. Huang, M. T.; Grollman, A. P. Mode of action of tylocrebrine: effects on protein and nucleic acid synthesis. Mol. Pharmacol. 1972, 8, 538- 550.
13. Donaldson, G. R.; Atkinson, M. R.; Murray, A. W. Inhibition of protein synthesis in Ehrlich ascites-tumour cells by the phenanthrene alkaloids tylophorine, tylocrebrine and cryptopleurine. Biochem. Biophys. Res. Commun. 1968, 31, 104-109.
14. Gao, W.; Chen, A. P.; Leung, C. H.; Gullen, E. A.; Furstner, A.; Shi, Q.; Wei, L.; Lee, K. H.; Cheng, Y. C. Structural analogs of tylophora alkaloids may not be functional analogs. Bioorg. Med. Chem. Lett. 2008, 18, 704-709.
15. Gao, W.; Lam, W.; Zhong, S.; Kaczmarek, C.; Baker, D. C.; Cheng, Y. C. Novel mode of action of tylophorine analogs as antitumor compounds. Cancer Res. 2004, 64, 678-688.
16. Ling, Y. H.; Consoli, U.; Tornos, C.; Andreeff, M.; Perez-Soler, R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with Taxol. Int. J. Cancer 1998, 75, 925-932.
17. Bacus, S. S.; Gudkov, A. V.; Lowe, M.; Lyass, L.; Yung, Y.; Komarov, A. P.; Keyomarsi, K.; Yarden, Y.; Seger, R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001, 20, 147-155.
18. Shiah, H. S.; Gao, W.; Baker, D. C.; Cheng, Y. C. Inhibition of cell growth and nuclear factor-kappaB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Mol. Cancer Ther. 2006, 5, 2484-2493.
19. Sen, R.; Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986, 46, 705-716.
20. Huber, M. A.; Azoitei, N.; Baumann, B.; Grunert, S.; Sommer, A.; Pehamberger, H.; Kraut, N.; Beug, H.; Wirth, T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. InVest. 2004, 114, 569-581.
21. Baldwin, A. S. Control of Oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. InVest. 2001, 107, 241-246.
22. Wang, C. Y.; Cusack, J. C., Jr.; Liu, R.; Baldwin, A. S., Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 1999, 5,412-417.
23. Bharti, A. C.; Aggarwal, B. B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem. Pharmacol. 2002, 64, 883-888.
24. Kim, H. J.; Hawke, N.; Baldwin, A. S. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006, 13, 738-747.
25. Romashkova, J. A.; Makarov, S. S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401, 86-90.
26. Ozes, O. N.; Mayo, L. D.; Gustin, J. A.; Pfeffer, S. R.; Pfeffer, L. M.; Donner, D. B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401, 82-85.
27. Lawrence, T.; Bebien, M.; Liu, G. Y.; Nizet, V.; Karin, M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005, 434, 1138-1143.
28. Saccani, S.; Pantano, S.; Natoli, G. Modulation of NF-kappaB activity by exchange of dimers. Mol. Cell 2003, 11, 1563-1574.
29. Xia, Y.; Pauza, M. E.; Feng, L.; Lo, D. RelB regulation of chemokine expression modulates local inflammation. Am. J. Pathol. 1997, 151, 375-387.
30. Lawrence, T.; Bebien, M. IKKalpha in the regulation of inflammation and adaptive immunity. Biochem. Soc. Trans. 2007, 35, 270-272.
31. Talapatra, S.; Thompson, C. B. Growth factor signaling in cell survival: implications for cancer treatment. J. Pharmacol. Exp. Ther. 2001, 298, 873-878.
32. Datta, S. R.; Brunet, A.; Greenberg, M. E. Cellular survival: a play in three Akts. Genes DeV. 1999, 13, 2905-2927.
33. Downward, J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 1998, 10, 262-267.
34. Roy, H. K.; Olusola, B. F.; Clemens, D. L.; Karolski, W. J.; Ratashak, A.; Lynch, H. T.; Smyrk, T. C. AKT proto-Oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002, 23, 201-205.
35. Brognard, J.; Clark, A. S.; Ni, Y.; Dennis, P. A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61, 3986-3997.
36. Liu, W.; Li, J.; Roth, R. A. Heregulin regulation of Akt/protein kinase B in breast cancer cells. Biochem. Biophys. Res. Commun. 1999, 261, 897-903.
37. Lynch, H. T.; Casey, M. J.; Lynch, J.; White, T. E.; Godwin, A. K. Genetics and ovarian carcinoma. Semin. Oncol. 1998, 25, 265-280.
38. Miwa, W.; Yasuda, J.; Murakami, Y.; Yashima, K.; Sugano, K.; Sekine, T.; Kono, A.; Egawa, S.; Yamaguchi, K.; Hayashizaki, Y.; Sekiya, T. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. Biochem. Biophys. Res. Commun. 1996, 225, 968-974.
39. Staal, S. P. Molecular cloning of the akt Oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 5034-5037.
40. del Peso, L.; Gonzalez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278, 687-689.
41. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231-241.
42. Weng, S. C.; Kashida, Y.; Kulp, S. K.; Wang, D.; Brueggemeier, R. W.; Shapiro, C. L.; Chen, C. S. Sensitizing estrogen receptornegative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol. Cancer Ther. 2008, 7, 800-808.
43. Suzuki, E.; Umezawa, K.; Bonavida, B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007, 26, 6184-6193.
44. Dan, H. C.; Cooper, M. J.; Cogswell, P. C.; Duncan, J. A.; Ting, J. P.; Baldwin, A. S. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes DeV. 2008, 22, 1490-1500.
45. Chen, J. J.; Peck, K.; Hong, T. M.; Yang, S. C.; Sher, Y. P.; Shih, J. Y.; Wu, R.; Cheng, J. L.; Roffler, S. R.; Wu, C. W.; Yang, P. C. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res. 2001, 61, 5223-5230.
46. Chu, Y. W.; Yang, P. C.; Yang, S. C.; Shyu, Y. C.; Hendrix, M. J.; Wu, R.; Wu, C. W. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol. 1997, 17, 353-360.
47. Yu, S. L.; Chen, H. W.; Yang, P. C.; Peck, K.; Tsai, M. H.; Chen, J. J.; Lin, F. Y. Differential gene expression in Gram-negative and Gram-positive sepsis. Am. J. Respir. Crit. Care Med. 2004, 169, 1135-1143.
48. Chen, H. W.; Yu, S. L.; Chen, W. J.; Yang, P. C.; Chien, C. T.; Chou, H. Y.; Li, H. N.; Peck, K.; Huang, C. H.; Lin, F. Y.; Chen, J. J.; Lee, Y. T. Dynamic changes of gene expression profiles during postnatal development of the heart in mice. Heart 2004, 90, 927-934.
49. Kanehisa, M.; Goto, S.; Kawashima, S.; Nakaya, A. The KEGG databases at GenomeNet. Nucleic Acids Res. 2002, 30, 42-46.
50. Wu, C. C.; Lin, J. C.; Yang, S. C.; Lin, C. W.; Chen, J. J.; Shih, J. Y.; Hong, T. M.; Yang, P. C. Modulation of the expression of the invasion-suppressor CRMP-1 by cyclooxygenase-2 inhibition via reciprocal regulation of Sp1 and C/EBP{alpha}. Mol. Cancer Ther. 2008, 7, 1365-1375.
51. Miao, F.; Gonzalo, I. G.; Lanting, L.; Natarajan, R. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J. Biol. Chem. 2004, 279, 18091-18097.
52. Chen, J. J.; Lin, Y. C.; Yao, P. L.; Yuan, A.; Chen, H. Y.; Shun, C. T.; Tsai, M. F.; Chen, C. H.; Yang, P. C. Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 2005, 23, 953-964.